Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection.
about
Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis CPredictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus.Evaluation of Fucosylated Haptoglobin and Mac-2 Binding Protein as Serum Biomarkers to Estimate Liver Fibrosis in Patients with Chronic Hepatitis C.Impact of hepatitis C virus eradication on hepatocellular carcinogenesis.Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals.Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication.Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs.Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review.Associations between single-nucleotide polymorphisms of human exonuclease 1 and the risk of hepatocellular carcinoma.Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression?Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma.Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C.The evolving relationship between adiponectin and insulin sensitivity in hepatitis C patients during viral clearance.Predictors of treatment efficacy and ALT non-normalization with sofosbuvir/ribavirin therapy for patients with hepatitis C virus genotype 2.Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of heRecovery of pan-genotypic and genotype-specific amino acid alterations in chronic hepatitis C after viral clearance: transition at the crossroad of metabolism and immunity.Characteristics and prognosis of hepatocellular carcinoma detected in patients with chronic hepatitis C after the eradication of hepatitis C virus: A multicenter study from Japan.Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal.Nonzero Risk of Hepatocellular Carcinoma Even after Sustained Virological Response.Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.Association of CAA and TATC Insertion/Deletion Genetic Polymorphisms in RTN4 3'-UTR with Hepatocellular Carcinoma Risk.Screening therapeutic targets of ribavirin in hepatocellular carcinoma.Molecular Mechanisms of Hepatocarcinogenesis Following Sustained Virological Response in Patients with Chronic Hepatitis C Virus Infectionhepatocellular carcinoma occurrence in hepatitis C cirrhotics treated with direct-acting antiviral agentsImpact of direct-acting antiviral agents on the development of hepatocellular carcinoma: evidence and pathophysiological issues
P2860
Q30235178-E6E8D250-11D4-465A-94A7-02064B00EE41Q35715916-D9531B33-4AE6-4D2E-800B-58A3BA49E559Q35965881-C322B0CB-8391-477F-80BD-ECD142BCC373Q35985401-43CFCBDC-0B1E-4942-A0F0-D46F9F4EEBE6Q36306768-2ACE96A1-5A76-46CA-83BC-5C20DBA0FE82Q37232717-9C4C1C76-2F05-4FB3-BF2B-18564217A865Q37582545-8FFADBD3-962F-432B-9B85-F5F7B5F8E73AQ37685491-BA96D15C-42A6-437D-BDCF-198A32309B43Q37699397-069CF7D6-7EFE-4936-924A-181FA92C871DQ38758591-814EA8D3-D93D-4483-A77A-F5AABE8EA54AQ38980732-D4CC5673-E335-4F0C-9863-8C801EBAAB60Q39695580-9A7A30BB-9E5A-4B27-B31E-7B376B2EBAA8Q40305062-04BDE998-D623-4142-99D6-8A9D26521666Q40343824-44F483D3-8694-49F3-AAE9-61ACF133AE0FQ40421566-B53EC53B-B818-42EA-BAFD-8EAADAF81892Q40481684-394F58DC-100B-4B1F-A8D4-9A85524B4654Q40934730-9F11CA7F-D0B3-4A0D-950D-97512A8C7CA0Q41449567-0A941637-F4D6-4A52-B9FA-F8F5650F3A84Q42400250-B3A59C64-E371-43D9-BE1D-0EC28684EF78Q52566943-2941CAB4-79BE-4A5F-89D1-73BFB71D7532Q54129822-7326DB46-EA19-4375-B750-D4027C8CB5D4Q55331757-007DAA65-E727-4FD3-AAF1-810C66CBE5A0Q57067833-726B1FED-CE4F-4C17-A1A6-F32B3EE4F21FQ57301080-BD162423-3155-48B1-B9C7-22D0454EFC58Q58541835-FCC4749D-8E4F-4B28-A385-D9F78B25DE19
P2860
Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Risk factors of hepatocellular ...... c hepatitis C virus infection.
@en
Risk factors of hepatocellular ...... c hepatitis C virus infection.
@nl
type
label
Risk factors of hepatocellular ...... c hepatitis C virus infection.
@en
Risk factors of hepatocellular ...... c hepatitis C virus infection.
@nl
prefLabel
Risk factors of hepatocellular ...... c hepatitis C virus infection.
@en
Risk factors of hepatocellular ...... c hepatitis C virus infection.
@nl
P2093
P2860
P356
P1476
Risk factors of hepatocellular ...... c hepatitis C virus infection.
@en
P2093
Akira Kanamori
Hidenori Toyoda
Makoto Tanikawa
Seiki Kiriyama
Shusuke Kitabatake
Takanori Ito
Takashi Kumada
Toshifumi Tada
Yasuhiro Hisanaga
P2860
P304
P356
10.1111/JGH.12915
P577
2015-07-01T00:00:00Z